Form 4: Regeneron Director Huda Y. Zoghbi Reports Stock and Option Acquisition

Director Huda Y. Zoghbi reports acquisition of Regeneron stock and stock options.

Summary

• On January 2, 2025, Huda Y. Zoghbi, a director of Regeneron Pharmaceuticals, acquired 166 shares of common stock.
• These shares were acquired as time-based vesting restricted stock units, each representing a contingent right to receive one share of Regeneron's common stock.
• Additionally, Zoghbi acquired 1,958 non-qualified stock options with an exercise price of $719.37.
• These options become exercisable in portions, starting from the date of the Issuer's first annual meeting of shareholders following the date of grant, and the remainder on the first anniversary of the grant date, expiring on January 2, 2035.
• Following these transactions, Zoghbi directly owns 1,548 shares of Regeneron common stock and 1,958 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock and option acquisition. The director's acquisition could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of stock and options by a director could be interpreted as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• The acquisition of shares and options by a director may have a minor positive impact on shareholder sentiment.

Key Dates